

36. (Amended) The DDS formulation according to claim 33 [or 34] which is a pharmaceutical composition for therapy of thyroid carcinoma.

38. (Amended) The DDS formulation according to claim 36 [or 37] wherein the nucleic acid is an antisense nucleic acid or a ribozyme.

39. (Amended) A diagnostic method according to claim 29 of thyroid carcinoma wherein a probe for LAR mRNA is used.

Remarks

The filing fee has been calculated in view of the claim amendments herein. Support for the amended claims is found throughout the specification as originally filed, including in SEQ ID NO: 1 and claims 1-39 as originally filed.

The amendments to the Sequence Listing are intended solely to assure compliance with US PTO format requirements (37 CFR 1.821 et. seq.) and not to substantially change any sequences in any way.

The amendments to the claims are intended solely to place the claims in more conventional US form, eliminate improper multiple dependencies, and reduce the filing fee by reducing surcharges for excess claims. The applicants do not intend to narrow the scope of the claimed invention in any way, and reserve the right to re-introduce claims in this application or in subsequent filings, such as divisional applications.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN

By:



David A. Gass
Registration No. 38,153
6300 Sears Tower
233 S. Wacker Drive
Chicago, Illinois 60606
Telephone: (312) 474-6300

December 8, 2000